Donation Policy of Swiss Cancer Research
The Swiss Cancer Research foundation is mainly financed by donations from the Swiss population.
We fundamentally assume that our donors are committed people who want to make an important contribution to achieving our mission. They place great trust in us, which is why we carefully dedicate every donation to research.
Due to its ethical principles, the Swiss Cancer Research foundation also pays attention to its origin when receiving funds. The following provisions govern the handling of donations from private individuals as well as from foundations and companies.
Reasons for refusal
The Swiss Cancer Research foundation reserves the right to reject donations whose origin is contrary to the values of our organisation or could impair our independence and neutrality or damage our reputation. Donations will not be accepted if:
- there is a suspicion of illegal activities such as drug trafficking, fraud, money laundering, etc., or the donation comes from manufacturers of products (e.g., tabacco) that have a demonstrable carcinogenic effect.
- the donation comes from manufacturers of products (e.g., tabacco) that have a demonstrable carcinogenic effect.
Subject to the exceptions listed below, the Swiss Cancer Research foundation verifies donations of CHF 25,000 or more (individually or cumulatively within a calendar year).
In the case of anonymous donations over CHF 5,000, we are committed to using the research options available to us. However, if these do not lead to a result, we reserve the right to accept the donation.
We only accept cash donations over CHF 5,000 if we know the identity of the donor and the verification has taken place.
If you have any questions or require further information, please do not hesitate to contact our donation service.
Phone: +41 31 389 93 00
Mon – Thu: 8.00 a.m. – 12.00 p.m. and 1.00 p.m. – 5.00 p.m.
Fri: 8.00 a.m. – 12.00 p.m. and 1.00 p.m. – 4.00 p.m.
Swiss Cancer Research foundation
Effingerstrasse 40, P.O. Box
This document will enter into force on 6 March 2020 with the approval of the Board of Trustees of Swiss Cancer Research.